Patents Represented by Attorney, Agent or Law Firm Deirdre L. Conley
-
Patent number: 6653287Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.Type: GrantFiled: September 13, 2000Date of Patent: November 25, 2003Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
-
Patent number: 6582928Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 2, 2000Date of Patent: June 24, 2003Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6387270Abstract: The present invention includes a system and method for transferring a selected solute species from a fluid mixture to a fluid media. The system of the present invention includes a convergent channel for passing a fluid mixture containing a selected species tangentially across the first surface of a porous membrane. A fluid media is directed to flow tangentially over the second surface of the membrane. As the fluid mixture and the fluid media flow on opposite sides of the membrane, the selected species traverses the membrane leaving the fluid mixture and entering the fluid media. The volumetric loss to the fluid mixture associated with the loss of the selected species is compensated for by the convergency of the channel. As a result a constant velocity is maintained over the membrane, maximizing the selectivity of the filtration process.Type: GrantFiled: October 19, 2000Date of Patent: May 14, 2002Assignee: Genentech, Inc.Inventor: Robert D. van Reis
-
Patent number: 6252051Abstract: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.Type: GrantFiled: July 30, 1998Date of Patent: June 26, 2001Assignee: Genentech, Inc.Inventors: Paul J. Godowski, Melanie Rose Mark, Dong Xiao Zhang
-
Patent number: 6221249Abstract: The present invention includes a system and method for transferring a selected solute species from a fluid mixture of a fluid media. The system of the present invention includes a convergent channel for passing a fluid mixture containing a selected species tangentially across the first surface of a porous membrane. A fluid media is directed to flow tangentially over the second surface of the membrane. As the fluid mixture and the fluid media flow on opposite sides of the membrane, the selected species traverses the membrane leaving the fluid mixture and entering the fluid media. The volumetric loss to the fluid mixture associated with the loss of the selected species is compensated for by the convergency of the channel. As a result a constant velocity is maintained over the membrane, maximizing the selectivity of the filtration process.Type: GrantFiled: February 10, 2000Date of Patent: April 24, 2001Assignee: Genentech, Inc.Inventor: Robert D. van Reis
-
Patent number: 6156733Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.Type: GrantFiled: February 13, 1998Date of Patent: December 5, 2000Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
-
Patent number: 6124435Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: December 22, 1998Date of Patent: September 26, 2000Assignee: Genetech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6117650Abstract: An assay to test for hypertrophic activity in myocytes is described where wells are precoated with D-MEM/F-12 and fetal calf serum, plated with myocytes, cultured, and any change in size of the cells is determined. The growth medium may contain insulin, transferrin and aprotinin.Type: GrantFiled: July 23, 1997Date of Patent: September 12, 2000Assignee: Genentech, Inc.Inventor: Kathleen King
-
Patent number: 6077940Abstract: The present invention is directed to novel methods for enhancing the ability to separate a species of interest from other different species present in a free solution mixture thereof which takes advantage of interactions that occur between soluble, small molecular weight ligands and the species of interest. The small molecular weight ligands employed in the present invention function to interact with a species of interest in a mixture of different species through either affinity, hydrophobic and/or ionic interactions, thereby altering the molecular weight, hydrodynamic volume and/or isoelectric point of the species of interest and rendering it separable from other component(s) in the mixture.Type: GrantFiled: December 24, 1997Date of Patent: June 20, 2000Assignee: Genentech, Inc.Inventor: Robert Van Reis
-
Patent number: 6054051Abstract: The present invention includes a system and method for transferring a selected solute species from a fluid mixture to a fluid media. The system of the present invention includes a convergent channel for passing a fluid mixture containing a selected species tangentially across the first surface of a porous membrane. A fluid media is directed to flow tangentially over the second surface of the membrane. As the fluid mixture and the fluid media flow on opposite sides of the membrane, the selected species traverses the membrane leaving the fluid mixture and entering the fluid media. The volumetric loss to the fluid mixture associated with the loss of the selected species is compensated for by the convergency of the channel. As a result a constant velocity is maintained over the membrane, maximizing the selectivity of the filtration process.Type: GrantFiled: December 17, 1996Date of Patent: April 25, 2000Assignee: Genentech, Inc.Inventor: Robert D. van Reis
-
Patent number: 6027650Abstract: The present invention relates to methods useful for purifying materials using adsorbent chromatography, preferably in an expanded bed or packed bed configuration without the need to use a moving packed bed adapter, thereby improving elution characteristics for the sample molecule of interest.Type: GrantFiled: February 16, 1999Date of Patent: February 22, 2000Assignee: Genentech, Inc.Inventors: Robert D. Van Reis, Gerardo A. Zapata
-
Patent number: 5929211Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: September 4, 1997Date of Patent: July 27, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5889155Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 31, 1995Date of Patent: March 30, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5837486Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.Type: GrantFiled: May 19, 1995Date of Patent: November 17, 1998Assignee: Genentech, Inc.Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
-
Patent number: 5830685Abstract: A novel bronchial or bronchiolar epithelial cell from normal neonatal mammalian lung has been isolated, established and maintained for multiple passages in the absence of serum, without undergoing crisis or senescence. By careful manipulation of the nutritional/hormonal microenvironment we have been able to select, from a heterogeneous population, a single epithelial cell type which can maintain highly differentiated features in vitro. This cell type has characteristics of bronchiolar epithelial cells. A clonal line, RL-65, has been selected and observed for more than 3 years in continuous culture. It has been characterized by ultrastructural, morphological and biochemical criteria.Type: GrantFiled: July 16, 1992Date of Patent: November 3, 1998Assignee: Genentech, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts
-
Patent number: 5801231Abstract: Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TGF-.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TGF-.beta. is useful in diagnosis and identification of TGF-.beta. clones.Type: GrantFiled: May 30, 1995Date of Patent: September 1, 1998Assignee: Genentech, Inc.Inventors: Rik M. A. Derynck, David V. Goeddel
-
Patent number: 5770704Abstract: The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.Type: GrantFiled: January 31, 1997Date of Patent: June 23, 1998Assignee: Genentech, Inc.Inventor: Paul J. Godowski
-
Patent number: 5763584Abstract: The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.Type: GrantFiled: May 5, 1995Date of Patent: June 9, 1998Assignee: Genentech, Inc.Inventor: Paul J. Godowski
-
Patent number: 5753219Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.Type: GrantFiled: May 15, 1995Date of Patent: May 19, 1998Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
-
Patent number: 5726290Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.Type: GrantFiled: May 19, 1995Date of Patent: March 10, 1998Assignee: Genentech, Inc.Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier